Navigation Links
Monoclonal antibodies show promise in treatment of blood cancer

Immunologists at Duke University Medical Center have found that a new monoclonal antibody that targets immune system B cells could be a pioneering treatment for leukemias, autoimmune diseases and transplant rejection//.

B cells are the main producers of antibodies, the body's defense mechanism against invading antigens. But the uncontrolled production of these B cells is responsible for leukemias such as multiple myeloma and acute lymphoblastic leukemia and autoimmune diseases like rheumatoid arthritis and lupus. The findings of the study have been published in the online Early Edition of the Proceedings of the National Academy of Sciences for the week October 10, 2005.

Professor and Chair of Immunology Thomas Tedder, Ph.D., Norhito Yazawa, Yasuhito Hamaguchi and Jonathan Poe in Tedder's laboratory are the co-authors of this report. Basically, monoclonal antibodies are directed against specific proteins. In this study, the Duke researchers targeted a surface protein called CD19, which is found on the B cells. When this was administered to laboratory mice, the researchers found that this reduced the number of B cells greatly. Significantly they also found that this monoclonal antibody behaved aggressively against B cell tumors. In 10 mice with malignant B cell lymphomas, the monoclonal antibody prevented the appearance of tissue tumor circulating cells for seven weeks. In contrast untreated mice died in three weeks. "We were actually quite shocked at how effectively CD19 mAb-treatments prevented malignant B cell expansion," said Tedder. "Treatment of such tumors in mouse models is extraordinarily difficult." Based on their findings, the researchers conclude, "In addition, this treatment could greatly aid transplant patients who require multiple organ transplants because they develop a humoral antibody response to their transplanted organs, or they already have preformed antibodies that prevent them from accepting some donor grafts."
'"/>




Page: 1

Related medicine news :

1. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
2. Monoclonal Anti-Body To Revolutionize Brain Cancer Treatment
3. Monoclonal Antibody based system for Anthrax detection
4. Monoclonal Antibody Reduces Exacerbations in Asthmatics
5. Survival of Mice With Human Breast Cancer Extended by Monoclonal Antibodies
6. Mutating viruses helps produce antibodies
7. Hybrid antibodies to protect from small pox infection
8. Gene Therapy shows promise in treating Hemophilia
9. Leukemia pill shows promise against stomach cancer
10. Stent shows promise in keeping arteries open
11. Drug to treat lung cancer shows promise
Post Your Comments:
(Date:10/8/2008)... , Dr. Robert Bernstein, ...rocedure for hair restoration is featured on the O...atment. , New York, NY (P...atures Dr. Bernstein discussing his pioneering fol...n the newest diagnostic and treatment techniques f...
(Date:10/7/2008)... U.S. recommendations reflect previously publ...LAS, Oct. 7 /PRNewswire-USNewswire/ -- Guidelines,...epartment of Health and,Human Services (HHS) were ...ts Medicine (ACSM) and the American Heart Associat...hed physical activity recommendations,last year, a...
(Date:10/7/2008)ANAHEIM, Calif., Oct. 7 /PRNewswire-USNewswire/ -- CHADD, the nation,s,largest organization serving people affected by AD/HD, will hold its Annual,International Conference on AD/HD November 12-1
(Date:10/7/2008)... Compression ultrasound similar to more expensive... , TUESDAY, Oct. 7 (HealthDay News) -- An o...leg -- called deep vein thrombosis, or DVT -- is a...esearch says. , European researchers found that...alled compression or duplex ultrasound -- was as g...
Breaking Medicine News(10 mins):Health News:Pioneering Hair Transplant Doctor Explains Procedure on Oprah Winfrey Show 2Health News:ACSM, AHA Support Federal Physical Activity Guidelines 2Health News:ACSM, AHA Support Federal Physical Activity Guidelines 3Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 3
...are commonly used for a number of painful complai... attack and stroke//. This has lead to an order by...rugs will have to carry a warning along with the i...turers. Doctors are being informed of the small ...
...nt study, women with a twin are at upto 5 times hi...an those without one//. The study was conducted o... The risk of premature ovarian failure (POF) at th...s than women from the general population. POF caus...
...lie Minogue with breast cancer has led to confusio...o get breast cancer//. Cancer Research UK said t...re likely to strike the under-70s than women over ...en revealed that 77 per cent of them thought that ...
...safe for administration in babies and toddlers, re...of flu shots//. Two flu seasons back, the federal...the age 6 months to 2 years and their family membe...ise in the number of children getting vaccinated. ...
Other Medicine News:
(Date:10/7/2008)... VIENNA, Va., Oct. 7 /...y that it has entered into a Material Transfer,Agr...h Clinical Center,(NIHCC) and the laboratory of Dr... molecular basis of changes to the tumor microenvi... Dr. Marincola is the Chief of,the Infectious Dise...
(Date:10/7/2008)... - Data Presented Today at ACG Annual Sc...wire-FirstCall/ -- Ironwood,Pharmaceuticals, Inc. ...,Inc. (NYSE: FRX ) today announced the presentati...clotide,s safety and efficacy in 420 patients with...). Analysis of the data,indicates that once- daily...
(Date:10/7/2008)... Several abstracts highlighting CIMZIA,s long...hn,s disease patients presented at American Colleg... /- Data from two studies,p...of Gastroenterology,(ACG) Annual Meeting demonstra...PEGylated anti-TNF alpha (Tumor Necrosis Factor al...
(Date:10/7/2008)... - Planned 15 Patient Cohort Enrolled in Stage A...ombination With Carboplatin and Paclitaxel -, TUS...grine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a cl...monoclonal antibodies for the treatment of cancer ...nced that it has completed,enrollment in the first...
Breaking Medicine Technology:CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4Doctors See How Cancer Drug Can Damage Kidneys 14210 1Doctors See How Cancer Drug Can Damage Kidneys 14210 2Doctors See How Cancer Drug Can Damage Kidneys 14210 3New Tools Boost Alzheimers Awareness 14206 1New Tools Boost Alzheimers Awareness 14206 2New Tools Boost Alzheimers Awareness 14206 3WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 1WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 2WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 3WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 4WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 5WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 6WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 7WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 8WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 9WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 10WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 11WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 12The Makers of Conquer HA 28TM 29 Launch All Natural Double Strength Anti Inflammatory Formula 14200 1The Makers of Conquer HA 28TM 29 Launch All Natural Double Strength Anti Inflammatory Formula 14200 2
The 6303 is an affordable path to Sonesta flexibility. Three motors provide full height, seat, and back adjustments. Packaged with basic accessories, the 6303 accepts the full line of Sonesta add-ons
For complete unobstructed imaging coverage for a wide range of urological procedures, HealthTronics urodynamics Chair/Table is the answer.
The Advanced Model BR2 Bilirubin STAT-Analyzer® provides a rapid, accurate determination of total and direct bilirubin in neonates. And because it's so compact and easy to use, it is appropriate
...e utilises a generic PCR amplification with biotin...on of an HLA locus. This is followed by hybridisat...nce Specific Oligonucleotide probes immobilised on...bes is referred to as a Reverse Line blot and thus...
Medicine Products: